Search
                    Alzheimer's Disease Clinical Trials in Greensboro, NC
A listing of 5  Alzheimer's Disease  clinical trials  in Greensboro, NC  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 5 of 5
        
        
    
                The city of Greensboro, North Carolina, currently has 5 active clinical trials seeking participants for Alzheimer's Disease research studies. 
            
                        Featured Trial
                
                Paid Clinical Studies Nationwide
            
        Recruiting
            
        Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
    
    
Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.             
        
        
    Gender:
                ALL
            Ages:
                Between 55 years and 90 years
            Trial Updated:
                08/14/2025
            
            Locations: Triad Clinical Trials, Greensboro, North Carolina         
        
        
            Conditions: Alzheimer Disease
        
            
        
    
                
                                    Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
                                
            
            
        Recruiting
                            
            
                This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028.
The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.             
        
        
    Gender:
                ALL
            Ages:
                Between 55 years and 90 years
            Trial Updated:
                08/11/2025
            
            Locations: Local Institution - 1221, Greensboro, North Carolina         
        
        
            Conditions: Psychosis Associated With Alzheimer's Disease
        
            
        
    
                
                                    A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.
Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 55 years and 80 years
            Trial Updated:
                07/30/2025
            
            Locations: Medication Management, Greensboro, North Carolina         
        
        
            Conditions: Alzheimer's Disease
        
            
        
    
                
                                    A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
                                
            
            
        Recruiting
                            
            
                The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.             
        
        
    Gender:
                ALL
            Ages:
                Between 65 years and 80 years
            Trial Updated:
                06/24/2025
            
            Locations: Care Access - Greensboro, Greensboro, North Carolina  +1 locations         
        
        
            Conditions: Alzheimer Disease
        
            
        
    
                
                                    Inspiring Seniors Towards Exercise Promotion to Protect Cognition
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to test the benefits of beat-accented music stimulation (BMS) for behavioral changes of physical activity (PA) in older adults with subjective memory complaints. Specific Aims are to determine (1) whether BMS beneficially influences PA behaviors and psychological responses to PA in older adults for 6 months, and (2) whether exercising with BMS differently influences physical and cognitive functioning as well as quality of life in older adults.To test the effect...  Read More             
        
        
    Gender:
                ALL
            Ages:
                65 years and above
            Trial Updated:
                03/19/2025
            
            Locations: UNC Greensboro, Greensboro, North Carolina         
        
        
            Conditions: Alzheimer Disease, Physical Activity
        
            
        
    1 - 5 of 5
            
            
        